Oxidative stress mediates neuronal DNA damage and apoptosis in response to cytosine arabinoside

被引:91
作者
Geller, HM
Cheng, KY
Goldsmith, NK
Romero, AA
Zhang, AL
Morris, EJ
Grandison, L
机构
[1] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA
[2] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA
关键词
antioxidant; cell death; comet; DNA strand break; flow cytometry; neuroprotection;
D O I
10.1046/j.1471-4159.2001.00395.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytosine arabinoside (AraC) is a nucleoside analog that produces significant neurotoxicity in cancer patients. The mechanism by which AraC causes neuronal death is a matter of some debate because the conventional understanding of AraC toxicity requires incorporation into newly synthesized DNA. Here we demonstrate that AraC-induced apoptosis of cultured cerebral cortical neurons is mediated by oxidative stress. AraC-induced cell death was reduced by treatment with several different free-radical scavengers (N-acetyl-L-cysteine, dipyridamole, uric acid, and vitamin E) and was increased following depletion of cellular glutathione stores. AraC induced the formation of reactive oxygen species in neurons as measured by an increase in the fluorescence of the dye 5-(6)-carboxy-2 ' ,7 ' -dichlorodihydrofluorescein diacetate. AraC produced DNA single-strand breaks as measured by single-cell gel electrophoresis and the level of DNA strand breakage was reduced by treatment with the free radical scavengers. These data support a model in which AraC induces neuronal apoptosis by provoking the generation of reactive oxygen species, causing oxidative DNA damage and initiating the p53-dependent apoptotic program. These observations suggest the use of antioxidant therapies to reduce neurotoxicity in AraC chemotherapeutic regimens.
引用
收藏
页码:265 / 275
页数:11
相关论文
共 62 条
  • [1] Both oxidative stress-dependent and independent effects of amyloid β protein are detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay
    Abe, K
    Saito, H
    [J]. BRAIN RESEARCH, 1999, 830 (01) : 146 - 154
  • [2] Anderson CNG, 1999, J NEUROSCI, V19, P664
  • [3] CYTARABINE AND NEUROLOGIC TOXICITY
    BAKER, WJ
    ROYER, GL
    WEISS, RB
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (04) : 679 - 693
  • [4] BALZARINI J, 1987, MOL PHARMACOL, V32, P798
  • [5] GROWTH OF A RAT NEUROBLASTOMA CELL LINE IN SERUM-FREE SUPPLEMENTED MEDIUM
    BOTTENSTEIN, JE
    SATO, GH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (01) : 514 - 517
  • [6] Bullock G, 1996, LEUKEMIA, V10, P1731
  • [7] Pharmacokinetics of high-dose cytarabine and its deamination product-A reappraisal
    Burk, M
    Heyll, A
    Arning, M
    Volmer, M
    Fartash, K
    Schneider, W
    [J]. LEUKEMIA & LYMPHOMA, 1997, 27 (3-4) : 321 - 327
  • [8] Hydroxyl radicals and DNA base damage
    Cadet, J
    Delatour, T
    Douki, T
    Gasparutto, D
    Pouget, JP
    Ravanat, JL
    Sauvaigo, S
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1999, 424 (1-2) : 9 - 21
  • [9] Cadet J, 1997, Rev Physiol Biochem Pharmacol, V131, P1
  • [10] Curative chemotherapy for acute myeloid leukemia: The development of high-dose ara-C from the laboratory to bedside
    Capizzi, RL
    [J]. INVESTIGATIONAL NEW DRUGS, 1996, 14 (03) : 249 - 256